Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Matt Scalo - Senior Vice President, Investor Relations Paul Diaz - President and Chief Executive Officer Mark Verratti - Chief Commercial Officer Bryan Riggsbee - Chief Financial Officer Conference Call Participants Elizabeth Koslosky - Goldman Sachs Andrew Cooper - Raymond James Daniel Sammarco - TD Cowen Jack Meehan - Nephron Research Wolf Chanoff - Bank of America Matt Scalo Good aftern ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ (Mark One) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15( ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2023 Results Conference Call August 3, 2023 4:30 PM ET Company Participants Matt Scalo - Senior Vice President, Investor Relations Paul Diaz - President and Chief Executive Officer Bryan Riggsbee - Chief Financial Officer Nicole Lambert - Chief Operating Officer Mark Verratti - Chief Commercial Officer Conference Call Participants Matt Sykes - Goldman Sachs Andrew Cooper - Raymond James Jack Meehan - Nephron Research Operator Greetings, and welcome to the Myriad Geneti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ (Mark One) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Financial Data and Key Metrics Changes - Myriad Genetics reported total revenue of $181.2 million for Q1 2023, reflecting a 10% year-over-year growth, marking the second consecutive quarter of double-digit revenue growth [28][30] - Total volumes grew organically by 21% year-over-year, with significant contributions from hereditary cancer testing and GeneSight [27][28] - Adjusted operating expenses for Q1 were $144.5 million, higher than previously anticipated due to performance-based commissions and sales and marketing costs [30] Business Line Data and Key Metrics Changes - The oncology business generated $77.6 million in revenue, with Prolaris volumes growing 22% year-over-year [12][13] - Women's health hereditary cancer testing volumes increased by 32% year-over-year, marking three consecutive quarters of positive growth [14][15] - GeneSight volumes grew by 31% year-over-year, with approximately 4,000 new clinicians ordering the test for the first time [16][17] Market Data and Key Metrics Changes - Prenatal testing volumes, excluding contributions from SneakPeek, grew by 12% year-over-year [27] - The company noted a strong performance in existing accounts, indicating that growth was primarily driven by wallet share rather than new customer acquisition [11][12] Company Strategy and Development Direction - Myriad Genetics is focused on maximizing the potential of its current products, including MyRisk, GeneSight, and Prolaris, while also investing in operational improvements and customer experience [20][21] - The company announced strategic partnerships, including an expanded collaboration with Illumina and a new partnership with SimonMed Imaging, aimed at enhancing access to genetic testing [6][25][26] - The Labs of the Future strategy is being implemented to improve operational efficiency and reduce costs [9][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability and positive operating cash flow by Q4 2023, despite challenges in the operating environment [31][33] - The management team emphasized the importance of maintaining stable pricing and effective capital deployment to support growth and shareholder value [33][34] Other Important Information - The company ended the quarter with $109 million in cash and no debt, indicating a strong balance sheet [32] - Myriad Genetics is actively working on enhancing its digital capabilities to improve customer engagement and streamline operations [18][19] Q&A Session Summary Question: Timeline for product pipeline updates - Management confirmed that there are no material changes to the product launch timelines, with FirstGene expected to launch in Q4 [40] Question: Clarification on operating expenses increase - Management explained that the increase in operating expenses was due to higher sales and marketing costs associated with increased volume, but they expect to control costs moving forward [41][42] Question: Productivity increase from EPIC EMR integration - Management indicated that they expect a 25% lift in volumes from EMR integrations, which will reduce friction with payers and improve operational efficiency [48][49] Question: Impact of COVID on growth comparisons - Management clarified that while there were easier comparisons due to COVID, the current growth is driven by strong performance across all product lines [52][53] Question: GeneSight ASP and billing issues - Management acknowledged a sequential decline in GeneSight ASP due to seasonality and billing issues, but emphasized overall revenue growth [57][58] Question: MRD assay market outlook - Management expressed excitement about the MRD assay and its differentiation in the market, with expectations for revenue generation in the back half of the year [64] Question: M&A strategy - Management confirmed that they are open to opportunistic acquisitions but are currently focused on maximizing profitability from existing products [66] Question: Cross-selling opportunities - Management highlighted early successes in cross-selling products across different channels, with ongoing efforts to enhance provider engagement [68][69]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ (Mark One) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Market ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O ...

Raymond James 2023 Institutional Investors Conference March 6, 2023 ©2023Myriad Genetics, Inc. All rights reserv™ed. ©2023Myriad Genetics, Inc. All rights reserved. www.Myriad.com Forward-looking statements and Non-GAAP financial measures Some of the information These statements are based on management’s current expectations and the actual presented here today may events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Matthew Scalo - SVP, Investor Relations Paul Diaz - CEO, President & Director Nicole Lambert - COO Bryan Riggsbee - EVP, CFO & Treasurer Mark Verratti - Chief Commercial Officer. Conference Call Participants Tom Stevens - Cowen and Company Jack Meehan - Nephron Research Operator Greetings, and welcome to the Myriad Genetics Fourth Quarter 2022 Financial Earnings Conference Call. During the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________ FORM 10-K _______________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |------------------------------------------------------------ ...

Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Matthew Scalo - SVP, Investor Relations Paul Diaz - CEO, President & Director Nicole Lambert - COO Bryan Riggsbee - EVP, CFO & Treasurer Conference Call Participants Daniel Brennan - Life Science & Diagnostic Tools Matthew Sykes - Goldman Sachs Jack Meehan - Nephron Research Mason Carrico - Stephens Incorporated Brandon Couillard - Jefferies Julia Kim - JPMorgan Puneet Souda - SVB Securities ...